Garth Strohbehn

Assistant Professor

University of Michigan Rogel Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Garth Strohbehn is an Assistant Professor at the University of Michigan Rogel Cancer Center in the United States. His research areas focus on clinical pharmacology, cancer drug optimization, and the effectiveness of immune checkpoint inhibitors. He has published recent articles examining the dosing strategies and impact of cancer therapies within diverse patient populations.

Articles (27)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Matthew J. Schipper

UNITED STATES

View details

Gregory Zaric

Professor

Western University

CANADA

View details

Michael J. Kelley

Duke University

UNITED STATES

View details

Michael Green

Assistant Professor

University of Michigan

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Garth Strohbehn

Research Interests

Explore related searches

Contact this professor

About

Articles (27)

Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority

Missed Opportunity for Sotorasib Dose Optimization

Non-inferiority trials: tyranny or good governance? – Authors' reply

Optimizing the doses of cancer drugs after usual dose finding

Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders

‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent

Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer

Special designations and the US Food and Drug Administration’s “dual mandate”

Immunotherapy in Prepatients - Preventing or Promoting a Malignant Transformation?

Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study

Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System

The tyranny of non-inferiority trials.

Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.

US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?

Targeted randomization dose optimization trials enable fractional dosing of scarce drugs

Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.

Dose optimisation and scarce resource allocation: two sides of the same coin.

Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer

Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation

Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings

De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer

Lorlatinib Exposed: A Far From Optimal Dose

Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan

Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab

Collaborators (4)

Matthew J. Schipper

Gregory Zaric

Michael J. Kelley

Michael Green

Make your next move.